CASI Pharmaceuticals Inc (CASI) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

CASI Pharmaceuticals Inc

NASDAQ | CASI

1.94

USD

+0.0089 (+0.46%)

AT CLOSE (AS OF Apr 17, 2025)

$30M

MARKET CAP

P/E Ratio

-2.56

EPS

$7.7

52 Week High

$1.9

52 Week Low

LIFE SCIENCES

Sector

CASI Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

CASI Technicals

Tags:

CASI Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$11M
Total Revenue	$29M
Cost Of Revenue	$17M
Costof Goods And Services Sold	$17M
Operating Income	-$40M
Selling General And Administrative	$24M
Research And Development	$8.9M
Operating Expenses	$51M
Investment Income Net	-
Net Interest Income	-$332K
Interest Income	$539K
Interest Expense	$871K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$2.3M
Income Before Tax	-$38M
Income Tax Expense	$1.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$39M
Comprehensive Income Net Of Tax	-
Ebit	-$37M
Ebitda	-$35M
Net Income	-$39M

Revenue & Profitability

Earnings Performance

CASI Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$54M
Total Current Assets	$40M
Cash And Cash Equivalents At Carrying Value	$13M
Cash And Short Term Investments	$13M
Inventory	$5.3M
Current Net Receivables	-
Total Non Current Assets	$14M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$238K
Intangible Assets Excluding Goodwill	$238K
Goodwill	-
Investments	-
Long Term Investments	$1.7M
Short Term Investments	$2.6M
Other Current Assets	$2.9M
Other Non Current Assets	-
Total Liabilities	$52M
Total Current Liabilities	$36M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$20M
Total Non Current Liabilities	$15M
Capital Lease Obligations	$3.8M
Long Term Debt	-
Current Long Term Debt	$18M
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$22M
Other Current Liabilities	$12M
Other Non Current Liabilities	$12M
Total Shareholder Equity	$1.9M
Treasury Stock	-
Retained Earnings	-$700M
Common Stock	$2K
Common Stock Shares Outstanding	$15M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$29M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$2.3M
Capital Expenditures	$240K
Change In Receivables	-
Change In Inventory	$5.8M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$15M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$0
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$39M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$11M
Total Revenue	$29M
Cost Of Revenue	$17M
Costof Goods And Services Sold	$17M
Operating Income	-$40M
Selling General And Administrative	$24M
Research And Development	$8.9M
Operating Expenses	$51M
Investment Income Net	-
Net Interest Income	-$332K
Interest Income	$539K
Interest Expense	$871K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$2.3M
Income Before Tax	-$38M
Income Tax Expense	$1.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$39M
Comprehensive Income Net Of Tax	-
Ebit	-$37M
Ebitda	-$35M
Net Income	-$39M

CASI News

CASI Profile

CASI Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

CASI $1.94 (+0.46%) Quote details